In patients with FGFR-2 mutant intrahepatic cholangiocarcinoma, futibatinib has demonstrated antitumor activity effectiveness and due to its irreversible binding mechanism, it is less vulnerable to on-target resistance mutations than other competing FGFR inhibitors such as pemigatinib and infigratinib [6]. Here, FGFR2 is linked to intrahepatic cholangiocarcinoma.